Determination of minimal clinically important change in early and advanced Parkinson's disease
Identifieur interne : 001710 ( Main/Curation ); précédent : 001709; suivant : 001711Determination of minimal clinically important change in early and advanced Parkinson's disease
Auteurs : Robert A. Hauser [États-Unis] ; Peggy Auinger [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2011-04.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Advanced stage, Antiparkinson Agents (therapeutic use), Clinical trial, Disability Evaluation, Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Humans, Indans (therapeutic use), Levodopa, Male, Nervous system diseases, Neuroprotective Agents (therapeutic use), Parkinson Disease (classification), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Placebo Effect, ROC Curve, Severity of Illness Index, Time Factors, Treatment, Treatment Outcome, clinical global impression, clinical trial, minimal clinically important change, treatment.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Indans, Neuroprotective Agents.
- classification : Parkinson Disease.
- drug therapy : Parkinson Disease.
- Disability Evaluation, Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Humans, Levodopa, Male, Placebo Effect, ROC Curve, Severity of Illness Index, Time Factors, Treatment Outcome.
Abstract
Two common primary efficacy outcome measures in Parkinson's disease (PD) are change in Unified Parkinson's Disease Rating Scale (UPDRS) scores in early PD and change in “off” time in patients with motor fluctuations. Defining the minimal clinically important change (MCIC) in these outcome measures is important to interpret the clinical relevance of changes observed in clinical trials and other situations. We analyzed data from 2 multicenter, placebo‐controlled, randomized clinical trials of rasagiline; TEMPO studied 404 early PD subjects, and PRESTO studied 472 levodopa‐treated subjects with motor fluctuations. An anchor‐based approach using clinical global impression of improvement (CGI‐I) was used to determine MCIC for UPDRS scores and daily “off” time. MCIC was defined as mean change in actively treated subjects rated minimally improved on CGI‐I. Receiver operating characteristic (ROC) curves defined optimal cutoffs discriminating between changed and unchanged subjects. MCIC for improvement in total UPDRS score (parts I–III) in early PD was determined to be −3.5 points based on mean scores and −3.0 points based on ROC curves. In addition, we found an MCIC for reduction in “off” time of 1.0 hours as defined by mean reduction in “off” time in active treated subjects self‐rated as minimally improved on CGI‐I minus mean reduction in “off” time in placebo‐treated subjects self‐rated as unchanged (1.9–0.9 hours). We hypothesize that many methodological factors can influence determination of the MCIC, and a range of values is likely to emerge from multiple studies. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23638
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001158
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :001158
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000443
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001363
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001363
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001381
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :003061
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :003061
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003061
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :001764
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000612
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :002706
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000638
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :001C28
Links to Exploration step
ISTEX:6AD41568559AA8DC0476C834E96F42BC72AE4B3FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Determination of minimal clinically important change in early and advanced Parkinson's disease</title>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</author>
<author><name sortKey="Auinger, Peggy" sort="Auinger, Peggy" uniqKey="Auinger P" first="Peggy" last="Auinger">Peggy Auinger</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:6AD41568559AA8DC0476C834E96F42BC72AE4B3F</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.1002/mds.23638</idno>
<idno type="url">https://api.istex.fr/document/6AD41568559AA8DC0476C834E96F42BC72AE4B3F/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001158</idno>
<idno type="wicri:Area/Istex/Curation">001158</idno>
<idno type="wicri:Area/Istex/Checkpoint">000443</idno>
<idno type="wicri:doubleKey">0885-3185:2011:Hauser R:determination:of:minimal</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:21437987</idno>
<idno type="wicri:Area/PubMed/Corpus">001363</idno>
<idno type="wicri:Area/PubMed/Curation">001363</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001381</idno>
<idno type="wicri:Area/Ncbi/Merge">003061</idno>
<idno type="wicri:Area/Ncbi/Curation">003061</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003061</idno>
<idno type="wicri:Area/Main/Merge">001764</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:11-0228426</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000612</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002706</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000638</idno>
<idno type="wicri:doubleKey">0885-3185:2011:Hauser R:determination:of:minimal</idno>
<idno type="wicri:Area/Main/Merge">001C28</idno>
<idno type="wicri:Area/Main/Curation">001710</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Determination of minimal clinically important change in early and advanced Parkinson's disease</title>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Neurology, Molecular Pharmacology, and Physiology, University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Auinger, Peggy" sort="Auinger, Peggy" uniqKey="Auinger P" first="Peggy" last="Auinger">Peggy Auinger</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2011-04">2011-04</date>
<biblScope unit="vol">26</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="813">813</biblScope>
<biblScope unit="page" to="818">818</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">6AD41568559AA8DC0476C834E96F42BC72AE4B3F</idno>
<idno type="DOI">10.1002/mds.23638</idno>
<idno type="ArticleID">MDS23638</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Advanced stage</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Clinical trial</term>
<term>Disability Evaluation</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Indans (therapeutic use)</term>
<term>Levodopa</term>
<term>Male</term>
<term>Nervous system diseases</term>
<term>Neuroprotective Agents (therapeutic use)</term>
<term>Parkinson Disease (classification)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Placebo Effect</term>
<term>ROC Curve</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
<term>Treatment</term>
<term>Treatment Outcome</term>
<term>clinical global impression</term>
<term>clinical trial</term>
<term>minimal clinically important change</term>
<term>treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Indans</term>
<term>Neuroprotective Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Disability Evaluation</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Male</term>
<term>Placebo Effect</term>
<term>ROC Curve</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Essai clinique</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
<term>Stade avancé</term>
<term>Traitement</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Two common primary efficacy outcome measures in Parkinson's disease (PD) are change in Unified Parkinson's Disease Rating Scale (UPDRS) scores in early PD and change in “off” time in patients with motor fluctuations. Defining the minimal clinically important change (MCIC) in these outcome measures is important to interpret the clinical relevance of changes observed in clinical trials and other situations. We analyzed data from 2 multicenter, placebo‐controlled, randomized clinical trials of rasagiline; TEMPO studied 404 early PD subjects, and PRESTO studied 472 levodopa‐treated subjects with motor fluctuations. An anchor‐based approach using clinical global impression of improvement (CGI‐I) was used to determine MCIC for UPDRS scores and daily “off” time. MCIC was defined as mean change in actively treated subjects rated minimally improved on CGI‐I. Receiver operating characteristic (ROC) curves defined optimal cutoffs discriminating between changed and unchanged subjects. MCIC for improvement in total UPDRS score (parts I–III) in early PD was determined to be −3.5 points based on mean scores and −3.0 points based on ROC curves. In addition, we found an MCIC for reduction in “off” time of 1.0 hours as defined by mean reduction in “off” time in active treated subjects self‐rated as minimally improved on CGI‐I minus mean reduction in “off” time in placebo‐treated subjects self‐rated as unchanged (1.9–0.9 hours). We hypothesize that many methodological factors can influence determination of the MCIC, and a range of values is likely to emerge from multiple studies. © 2011 Movement Disorder Society</div>
</front>
</TEI>
<double idat="0885-3185:2011:Hauser R:determination:of:minimal"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Determination of Minimal Clinically Important Change in Early and Advanced Parkinson's Disease</title>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Departments of Neurology, Molecular Pharmacology, and Physiology, University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Auinger, Peggy" sort="Auinger, Peggy" uniqKey="Auinger P" first="Peggy" last="Auinger">Peggy Auinger</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Neurology, Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0228426</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 11-0228426 INIST</idno>
<idno type="RBID">Pascal:11-0228426</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000612</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002706</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000638</idno>
<idno type="wicri:doubleKey">0885-3185:2011:Hauser R:determination:of:minimal</idno>
<idno type="wicri:Area/Main/Merge">001C28</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Determination of Minimal Clinically Important Change in Early and Advanced Parkinson's Disease</title>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Departments of Neurology, Molecular Pharmacology, and Physiology, University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Auinger, Peggy" sort="Auinger, Peggy" uniqKey="Auinger P" first="Peggy" last="Auinger">Peggy Auinger</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Neurology, Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Advanced stage</term>
<term>Clinical trial</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
<term>Stade avancé</term>
<term>Traitement</term>
<term>Essai clinique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Two common primary efficacy outcome measures in Parkinson's disease (PD) are change in Unified Parkinson's Disease Rating Scale (UPDRS) scores in early PD and change in "off" time in patients with motor fluctuations. Defining the minimal clinically important change (MCIC) in these outcome measures is important to interpret the clinical relevance of changes observed in clinical trials and other situations. We analyzed data from 2 multicenter, placebo-controlled, randomized clinical trials of rasagiline; TEMPO studied 404 early PD subjects, and PRESTO studied 472 levodopa-treated subjects with motor fluctuations. An anchor-based approach using clinical global impression of improvement (CGI-I) was used to determine MCIC for UPDRS scores and daily "off" time. MCIC was defined as mean change in actively treated subjects rated minimally improved on CGI-I. Receiver operating characteristic (ROC) curves defined optimal cutoffs discriminating between changed and unchanged subjects. MCIC for improvement in total UPDRS score (parts I-III) in early PD was determined to be -3.5 points based on mean scores and -3.0 points based on ROC curves. In addition, we found an MCIC for reduction in "off" time of 1.0 hours as defined by mean reduction in "off" time in active treated subjects self-rated as minimally improved on CGI-I minus mean reduction in "off" time in placebo-treated subjects self-rated as unchanged (1.9-0.9 hours). We hypothesize that many methodological factors can influence determination of the MCIC, and a range of values is likely to emerge from multiple studies.</div>
</front>
</TEI>
</INIST>
<ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Determination of minimal clinically important change in early and advanced Parkinson's disease</title>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</author>
<author><name sortKey="Auinger, Peggy" sort="Auinger, Peggy" uniqKey="Auinger P" first="Peggy" last="Auinger">Peggy Auinger</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:6AD41568559AA8DC0476C834E96F42BC72AE4B3F</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.1002/mds.23638</idno>
<idno type="url">https://api.istex.fr/document/6AD41568559AA8DC0476C834E96F42BC72AE4B3F/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001158</idno>
<idno type="wicri:Area/Istex/Curation">001158</idno>
<idno type="wicri:Area/Istex/Checkpoint">000443</idno>
<idno type="wicri:doubleKey">0885-3185:2011:Hauser R:determination:of:minimal</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:21437987</idno>
<idno type="wicri:Area/PubMed/Corpus">001363</idno>
<idno type="wicri:Area/PubMed/Curation">001363</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001381</idno>
<idno type="wicri:Area/Ncbi/Merge">003061</idno>
<idno type="wicri:Area/Ncbi/Curation">003061</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003061</idno>
<idno type="wicri:Area/Main/Merge">001764</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Determination of minimal clinically important change in early and advanced Parkinson's disease</title>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Neurology, Molecular Pharmacology, and Physiology, University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Auinger, Peggy" sort="Auinger, Peggy" uniqKey="Auinger P" first="Peggy" last="Auinger">Peggy Auinger</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2011-04">2011-04</date>
<biblScope unit="vol">26</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="813">813</biblScope>
<biblScope unit="page" to="818">818</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">6AD41568559AA8DC0476C834E96F42BC72AE4B3F</idno>
<idno type="DOI">10.1002/mds.23638</idno>
<idno type="ArticleID">MDS23638</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (therapeutic use)</term>
<term>Disability Evaluation</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Indans (therapeutic use)</term>
<term>Levodopa</term>
<term>Male</term>
<term>Neuroprotective Agents (therapeutic use)</term>
<term>Parkinson Disease (classification)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson's disease</term>
<term>Placebo Effect</term>
<term>ROC Curve</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
<term>clinical global impression</term>
<term>clinical trial</term>
<term>minimal clinically important change</term>
<term>treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Indans</term>
<term>Neuroprotective Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Disability Evaluation</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Male</term>
<term>Placebo Effect</term>
<term>ROC Curve</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Two common primary efficacy outcome measures in Parkinson's disease (PD) are change in Unified Parkinson's Disease Rating Scale (UPDRS) scores in early PD and change in “off” time in patients with motor fluctuations. Defining the minimal clinically important change (MCIC) in these outcome measures is important to interpret the clinical relevance of changes observed in clinical trials and other situations. We analyzed data from 2 multicenter, placebo‐controlled, randomized clinical trials of rasagiline; TEMPO studied 404 early PD subjects, and PRESTO studied 472 levodopa‐treated subjects with motor fluctuations. An anchor‐based approach using clinical global impression of improvement (CGI‐I) was used to determine MCIC for UPDRS scores and daily “off” time. MCIC was defined as mean change in actively treated subjects rated minimally improved on CGI‐I. Receiver operating characteristic (ROC) curves defined optimal cutoffs discriminating between changed and unchanged subjects. MCIC for improvement in total UPDRS score (parts I–III) in early PD was determined to be −3.5 points based on mean scores and −3.0 points based on ROC curves. In addition, we found an MCIC for reduction in “off” time of 1.0 hours as defined by mean reduction in “off” time in active treated subjects self‐rated as minimally improved on CGI‐I minus mean reduction in “off” time in placebo‐treated subjects self‐rated as unchanged (1.9–0.9 hours). We hypothesize that many methodological factors can influence determination of the MCIC, and a range of values is likely to emerge from multiple studies. © 2011 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001710 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001710 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:6AD41568559AA8DC0476C834E96F42BC72AE4B3F |texte= Determination of minimal clinically important change in early and advanced Parkinson's disease }}
This area was generated with Dilib version V0.6.23. |